Clinical Trial Update: Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial conducted by Sichuan University is evaluating a combination of chidamide with cladribine, gemcitabine, and busulfan followed by autolog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Chidamide (chidamide)
• Cladribine (cladribine)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Sichuan University | Conditions: Hodgkin Lymphoma, Non-hodgkin Lymphoma | Phase 2 | Status: UNKNOWN